Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

173 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.
Ewertz M, Gray KP, Regan MM, Ejlertsen B, Price KN, Thürlimann B, Bonnefoi H, Forbes JF, Paridaens RJ, Rabaglio M, Gelber RD, Colleoni M, Láng I, Smith IE, Coates AS, Goldhirsch A, Mouridsen HT. Ewertz M, et al. Among authors: bonnefoi h. J Clin Oncol. 2012 Nov 10;30(32):3967-75. doi: 10.1200/JCO.2011.40.8666. Epub 2012 Oct 8. J Clin Oncol. 2012. PMID: 23045588 Free PMC article. Clinical Trial.
Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK).
Thürlimann B, Castiglione M, Hsu-Schmitz SF, Cavalli F, Bonnefoi H, Fey MF, Morant R, Löhnert T, Goldhirsch A. Thürlimann B, et al. Among authors: bonnefoi h. Eur J Cancer. 1997 Jun;33(7):1017-24. doi: 10.1016/s0959-8049(97)00105-6. Eur J Cancer. 1997. PMID: 9376181 Clinical Trial.
Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK).
Bernhard J, Castiglione-Gertsch M, Schmitz SF, Thürlimann B, Cavalli F, Morant R, Fey MF, Bonnefoi H, Goldhirsch A, Hürny C. Bernhard J, et al. Among authors: bonnefoi h. Eur J Cancer. 1999 Jun;35(6):913-20. doi: 10.1016/s0959-8049(99)00028-3. Eur J Cancer. 1999. PMID: 10533471 Clinical Trial.
Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?
Sabbioni ME, Bernhard J, Siegrist HP, Schmitz SF, Gertsch MC, Thürlimann B, Bonnefoi H, Perey L, Herrmann R, Goldhirsch A, Hürny C; Swiss Group for Clinical Cancer Research (SAKK). Sabbioni ME, et al. Among authors: bonnefoi h. Breast Cancer Res Treat. 2004 Sep;87(1):75-86. doi: 10.1023/B:BREA.0000041584.53863.a7. Breast Cancer Res Treat. 2004. PMID: 15377853 Free article. Clinical Trial.
173 results